Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LMP 420

Drug Profile

LMP 420

Alternative Names: LMP-420

Latest Information Update: 01 Mar 2011

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of North Carolina at Chapel Hill
  • Developer LeukoMed
  • Class Antirheumatics; Inorganic boron compounds; Purines
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Crohn's disease; Rheumatoid arthritis

Most Recent Events

  • 17 May 2007 This programme is still in active development
  • 27 Sep 2002 LMP 420 is available for licensing in the US and Europe (http://www.leukomed.com)
  • 27 Sep 2002 Preclinical trials in Crohn's disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top